Ian Deveau PhD U.S. FDA

Ian Deveau is Deputy Director for Quality in the Office of Compounding Quality and Compliance (OCQC), Office of Compliance, CDER. Dr. Deveau oversees the efforts to protect the American public from poor quality drug products and ensure compliance of firms authorized by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA). Dr. Deveau is a subject matter expert on sterile drug production, Current Good Manufacturing Practices (21 CFR 210, 211 & 212), and pharmacy compounding practices (USP <795> and <797>).

Dr. Deveau received a Bachelor’s in Biology at Buffalo State University and holds a PhD in Biology from The Pennsylvania State University with minors in Microbiology, Chemistry, and Biochemistry. Prior to joining CDER, he was a chemist and GLP Study Director at FDA’s Center for Veterinary Medicine, followed by 9 years at the U.S. Pharmacopeia involved in developing standards for microbial control of drug manufacturing, blood and blood products, vaccines, biologics and biotechnology products, radiopharmaceuticals & medical imaging agents, and veterinary drugs.